Carboplatin in combination therapy for ovarian cancer

W. W. ten Bokkel Huinink; M. E L van der Burg; A. T. van Oosterom; J. P. Neijt; M. George; J. P. Guastalla; C. H N Veenhof; N. Rotmensz; O. Dalesio; J. B. Vermorken

doi:10.1016/0305-7372(88)90030-8

Carboplatin in combination therapy for ovarian cancer

W. W. ten Bokkel Huinink, M. E L van der Burg, A. T. van Oosterom, J. P. Neijt, M. George, J. P. Guastalla, C. H N Veenhof, N. Rotmensz, O. Dalesio, J. B. Vermorken

Istituto Europeo di Oncologia

Research output: Contribution to journal › Article › peer-review

Abstract

Cisplatin today is a cornerstone of combination chemotherapy for ovarian cancer. Carboplatin seems equal to cisplatin in antitumour activity, but has a different toxicity profile. After a feasibility study, a randomized phase III study in ovarian cancer stage II, III, and IV was undertaken, comparing carboplatin with cisplatin in combination with cyclophosphamide, doxorubicin and hexamethylmelamine. Preliminary analysis of this study reveals no statistically significant difference in response rate. Notwithstanding equal haematological toxicity, the other side effects evoked by carboplatin in combination treatment are much milder than those evoked by cisplatin. Further analysis will be necessary to draw definite conclusions about the results obtained.

Original language	English
Pages (from-to)	9-15
Number of pages	7
Journal	Cancer Treatment Reviews
Volume	15
Issue number	SUPPL. B
DOIs	https://doi.org/10.1016/0305-7372(88)90030-8
Publication status	Published - 1988

ASJC Scopus subject areas

Oncology
Urology

Access to Document

10.1016/0305-7372(88)90030-8

Cite this

@article{ac33dd425d06408bb45474c6eceb00c5,

title = "Carboplatin in combination therapy for ovarian cancer",

abstract = "Cisplatin today is a cornerstone of combination chemotherapy for ovarian cancer. Carboplatin seems equal to cisplatin in antitumour activity, but has a different toxicity profile. After a feasibility study, a randomized phase III study in ovarian cancer stage II, III, and IV was undertaken, comparing carboplatin with cisplatin in combination with cyclophosphamide, doxorubicin and hexamethylmelamine. Preliminary analysis of this study reveals no statistically significant difference in response rate. Notwithstanding equal haematological toxicity, the other side effects evoked by carboplatin in combination treatment are much milder than those evoked by cisplatin. Further analysis will be necessary to draw definite conclusions about the results obtained.",

author = "{ten Bokkel Huinink}, {W. W.} and {van der Burg}, {M. E L} and {van Oosterom}, {A. T.} and Neijt, {J. P.} and M. George and Guastalla, {J. P.} and Veenhof, {C. H N} and N. Rotmensz and O. Dalesio and Vermorken, {J. B.}",

year = "1988",

doi = "10.1016/0305-7372(88)90030-8",

language = "English",

volume = "15",

pages = "9--15",

journal = "Cancer Treatment Reviews",

issn = "0305-7372",

publisher = "W.B. Saunders Ltd",

number = "SUPPL. B",

}

TY - JOUR

T1 - Carboplatin in combination therapy for ovarian cancer

AU - ten Bokkel Huinink, W. W.

AU - van der Burg, M. E L

AU - van Oosterom, A. T.

AU - Neijt, J. P.

AU - George, M.

AU - Guastalla, J. P.

AU - Veenhof, C. H N

AU - Rotmensz, N.

AU - Dalesio, O.

AU - Vermorken, J. B.

PY - 1988

Y1 - 1988

N2 - Cisplatin today is a cornerstone of combination chemotherapy for ovarian cancer. Carboplatin seems equal to cisplatin in antitumour activity, but has a different toxicity profile. After a feasibility study, a randomized phase III study in ovarian cancer stage II, III, and IV was undertaken, comparing carboplatin with cisplatin in combination with cyclophosphamide, doxorubicin and hexamethylmelamine. Preliminary analysis of this study reveals no statistically significant difference in response rate. Notwithstanding equal haematological toxicity, the other side effects evoked by carboplatin in combination treatment are much milder than those evoked by cisplatin. Further analysis will be necessary to draw definite conclusions about the results obtained.

AB - Cisplatin today is a cornerstone of combination chemotherapy for ovarian cancer. Carboplatin seems equal to cisplatin in antitumour activity, but has a different toxicity profile. After a feasibility study, a randomized phase III study in ovarian cancer stage II, III, and IV was undertaken, comparing carboplatin with cisplatin in combination with cyclophosphamide, doxorubicin and hexamethylmelamine. Preliminary analysis of this study reveals no statistically significant difference in response rate. Notwithstanding equal haematological toxicity, the other side effects evoked by carboplatin in combination treatment are much milder than those evoked by cisplatin. Further analysis will be necessary to draw definite conclusions about the results obtained.

UR - http://www.scopus.com/inward/record.url?scp=0023711367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023711367&partnerID=8YFLogxK

U2 - 10.1016/0305-7372(88)90030-8

DO - 10.1016/0305-7372(88)90030-8

M3 - Article

C2 - 3135934

AN - SCOPUS:0023711367

SN - 0305-7372

VL - 15

SP - 9

EP - 15

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

IS - SUPPL. B

ER -

Carboplatin in combination therapy for ovarian cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this